Although the immunotherapy using CD19-specific CAR T cells is quite effective for B cell lymphomas that commonly express CD191, applying this method to treat other types of cancers is challenging because of variations of cancer antigens among different cancer types and individual patients. The gene discussed is CCR1; the disease is cancer.